News

New Study to Treat Cystic Fibrosis Patients with Diabetic Complications

ProMetic Life Sciences Inc. announced plans to initiate a Phase 2 clinical trial to test its anti-fibrotic lead drug candidate PBI-4050 in cystic fibrosis (CF) patients with related diabetes as well as liver steatosis. Cystic fibrosis is a chronic disease of the lungs and, less frequently, of the pancreas, liver, kidneys, and gut,…

College Football Player Wins Annual Award Supporting CF Funding

Ryan Kelly has been named the 17th football player to win the 2015 Rimington Trophy. The award, which was announced last Thursday on December 10 according to a recent press release, is given annually to the Most Outstanding Center in NCAA Division I-A College Football in the U.S., and is determined by a consensus of All-American…

3 New CF Virulence Factors ID’d in Genome-wide Screen of Pathogen

In a new study, researchers describe the results of a genome-wide screen of Pseudomonas aeruginosa in a yeast, which led to the identification of three potential new Pseudomonas virulence factors. The research paper, entitled “Genome-wide Screen of Pseudomonas aeruginosa in Saccharomyces cerevisiae Identifies New Virulence Factors,” was published in Frontiers in Cellular and…

60-Year-Old Art Scholar is Also a Cystic Fibrosis Fighter

Luanne McKinnon, like many cystic fibrosis (CF) patients, is a determined achiever who lives life to its fullest — even earning a doctorate in art history at age 60. Her story was the subject of a recent profile in The University of Virginia’s online newspaper, UVA Today. McKinnon, who was awarded her PhD…

CF Foundation Bolstered by Support from Harvard Assets, Jeb Bush

Harvard Assets, a Pennsylvania-based provider of bullion and investment-grade diamond, recently renewed its support to the Cystic Fibrosis Foundation (CFF) and its mission of supporting the development of new drugs to fight cystic fibrosis (CF), improving the quality of life for those with the disease, and ultimately finding a cure. John Tucker,…

Cystic Fibrosis Phase 2 Trial of Drug Aiming to Stabilize Key CF Gene Underway

Nivalis Therapeutics, Inc., a Boulder, Colorado-based clinical stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The purpose of this double-blind, randomized, placebo-controlled, parallel group study…

Cystic Fibrosis Mutation May Change How Proteins Communicate

Protein interactions could be misdirected in people with cystic fibrosis (CF), causing a loss of normal protein function, according to researchers from the Scripps Research Institute (TSRI) in San Diego, California. The new study, titled “∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis“ appeared online on Nov. 30, 2015, ahead…

CF Foundation’s Annual Golf Charity Raises $630,000 to Support Community

The Cystic Fibrosis Foundation’s 2015 Ultimate Golf Experience, which ran four days beginning on Oct. 21, raised $630,000 towards continuing the organization’s mission of promoting disease research and awareness. Over 200 people attended the tournament at the Ritz-Carlton Dove Mountain resort in Tucson, Arizona. The event was hailed as a success and a source of much-needed…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.